Silver Creek (Drug Discovery) Overview

  • Founded
  • 2010
Founded
  • Status
  • Private
  • Employees
  • 6
Employees
  • Latest Deal Type
  • 2ndary - Private
  • Latest Deal Amount
  • $9.2M
Latest Deal Amount
  • Investors
  • 6

Silver Creek (Drug Discovery) General Information

Description

Manufacturer of medicines intended to create therapies that enhance the body's healing response and repair damaged tissue. The company's novel regenerative medicines stimulate stem cell-based regeneration of cardiovascular tissues after a cardiac infarction, offers bio-therapeutics that can promote resilience and regeneration of cells while minimizing unwanted effects in other tissues, enabling patients with the required regenerative medicines to protect or repair heart tissue following a heart attack.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Drug Discovery
Primary Office
  • 409 Illinois Street
  • San Francisco, CA 94158
  • United States
+1 (415) 000-0000

Silver Creek (Drug Discovery) Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Silver Creek (Drug Discovery) Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Secondary Transaction - Private 10-May-2019 $9.2M 000.00 Completed Generating Revenue
6. Later Stage VC 05-Feb-2018 0000 000.00 Completed Generating Revenue
5. Accelerator/Incubator 000.00 Completed Generating Revenue
4. Later Stage VC (Series C) 16-Dec-2016 00.000 000.00 0000 Completed Generating Revenue
3. Grant 05-May-2015 00000 000.00 Completed Startup
2. Early Stage VC (Series B) 01-Apr-2015 $2.1M $21.1M 000.00 Completed Startup
1. Early Stage VC (Series A) 21-Apr-2014 $19M $19M 0000 Completed Startup
To view Silver Creek (Drug Discovery)’s complete valuation and funding history, request access »

Silver Creek (Drug Discovery) Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C 00,000,000 00.000000 00.0 00.0 00.0 00 00.0 0.00
Series B 0,000,000 00.000000 00.00 00.00 00.00 00 00.00 0.000
Series A 19,836,652 $0.000100 $0.07 $1 $1 1x $1 66.12%
To view Silver Creek (Drug Discovery)’s complete cap table history, request access »

Silver Creek (Drug Discovery) Executive Team (5)

Name Title Board Seat Contact Info
Kris Kuchenbecker Ph.D Chief Technology Officer and Lead Scientist
Lakhmir Chawla MD Chief Medical Officer
You’re viewing 2 of 5 executive team members. Get the full list »

Silver Creek (Drug Discovery) Board Members (9)

Name Representing Role Since
James Marks Self Board Member 000 0000
Mark Agne Self Board Member 000 0000
Nicholas Taylor Self Board Member 000 0000
Thomas Murtagh Self Board Member 000 0000
Timothy Throsby Self Chairman 000 0000
You’re viewing 5 of 9 board members. Get the full list »

Silver Creek (Drug Discovery) Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Silver Creek (Drug Discovery) Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Mark Agne Angel (individual) Minority 000 0000 000000 0
Merrimack Pharmaceuticals Corporation Minority 000 0000 000000 0
National Institutes of Health Government 000 0000 000000 0
Crocker Ventures PE/Buyout Minority 000 0000 000000 0
Nicholas Taylor Angel (individual) Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »